Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

DOI Web Site Web Site 被引用文献6件

収録刊行物

  • The Lancet

    The Lancet 386 (10008), 2078-2088, 2015-11

    Elsevier BV

被引用文献 (6)*注記

もっと見る

問題の指摘

ページトップへ